David Hutton

The delivery of VivaVision's molecules via the suprachoroidal space using Everads' technology is expected to lead to novel treatments for retinal diseases.

A team of researchers from the University of Wisconsin–Madison developed a way to grow organized clusters of cells, called organoids, that resemble the retina, the light-sensitive tissue at the back of the eye.

Baumal replaces Federico Grossi, MD, PhD, who plans to remain at Apellis until Feb. 28 to help with the transition and preparations for the potential launch of pegcetacoplan for geographic atrophy.

According to the company, its announcement represents the first time eyecare professionals have been able to stock a fortified or high-concentration compounded antibiotic formulation for the immediate treatment of patients in need.

New educational campaign aims to educate individuals at risk for glaucoma and raise funding for glaucoma research.

eSight is previewing its eSight Go, a wearable device that allows users to gain a level of independence.

Researchers at Washington University School of Medicine in St. Louis have found that proteins made by stem cells that regenerate the cornea may be new targets for treating and preventing such injuries.

According to the company, the NDA is based on data from the Phase 3 NEAR-1 and NEAR-2 clinical trials, involving more than 600 patients, which evaluated the efficacy and safety of CSF-1.

The technique provides model for studying genesis of age-related macular degeneration and other eye diseases.

Derek Hodkey, president and CEO of Orbis International, discusses key achievements for the company and its Flying Eye Hospital in 2022 and offers his outlook for 2023.

According to the company, it is on track to initiate a Phase 2b trial in the first quarter of 2023, with topline data expected in the first quarter of 2024.

Researchers are looking for improved detection of disease in patients.

Janey Wiggs, MD, PhD, associate chief of Ophthalmology Clinical Research at Massachusetts Eye & Ear discusses genetics of glaucoma, providing an overview of what is known about genes and gene mutations that can cause or contribute to glaucoma.

According to a news release, Opus will advance preclinical development programs for BEST1– and RHO-related retinal diseases. The deal expands the company’s addressable patient population for its novel treatments for rare inherited retinal diseases.

According to investigators, the study demonstrated that by restoring the function of ADAM10, a major shedding protein, it was possible in preclinical models to control the abnormal formation of blood vessels, offering an attractive therapeutic target to treat DR.

The National Institute on Aging of the National Institutes of Health (NIH) is expanding the effort to understand that connection with a $10.3 million grant.

According to investigators, the study used curated real-world data from the IRIS Registry to report risk of progression by stage.

The company’s collaboration leverages MyEyeDr.’s 850+ offices across the United States to refer patients into ophthalmology and other therapeutic area clinical trials, expands Parexel’s Community Alliance Network to bring trials to patients where they are.

Wills Eye Hospital’s annual Give Kids Sight Day provides access to eyecare for children.

The study aims to understand how SARS-CoV-2 affects the eyes and whether it could serve as a virus infection route.

The company said the submission follows the FDA acceptance of the ONS-5010 BLA for the treatment of wet AMD, with a PDUFA date of August 29, 2023.

According to a team of investigators from the University of Michigan, the findings could help inform treatments for blindness in humans.

Scientists from the Clear Vision Research Lab at The Australian National University and the Korean biotech company MDimune Inc. hope to turn recent research milestones into potential treatments for AMD.

Retinopathy of prematurity is thought to be a two-stage disorder that begins with the arrested development of the retinal vessels in preterm babies when exposed to high oxygen levels at birth.

The Cell and Gene Therapy Center will combine a team of 100 researchers to capitalize on the company’s 35 years of cell and gene therapy experience.

On Tuesday, lawmakers unveiled the $1.7 trillion proposed spending package needed to avert a government shutdown by Friday if both chambers can pass the measure this week.

Previous research conducted primarily by scientists at the University of São Paulo, Brazil, showed brilacidin can potentiate several marketed antifungals, including caspofungin, voriconazole and posaconazole.

The company confirms target read-out around the end of 2023 and regulatory submission in Europe in H1 2024. The data will also play an important supporting role in U.S. regulatory submission.

STAAR Surgical President and CEO Caren Mason will be retiring December 31, and ophthalmic industry executive Thomas “Tom” G. Frinzi has been tapped as her replacement.

Company officials point out that RZ402 is an oral therapy being developed as a potential alternative to invasive and suboptimal injections into the eye.